Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL938 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Teligene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**TL938 + trastuzumab** is a combination therapy under investigation for the treatment of HER2-positive metastatic or advanced colorectal cancer. TL938 is a small molecule HER2 (Receptor tyrosine-protein kinase erbB-2) antagonist developed by SuZhou Teligene, while trastuzumab is a HER2-targeted monoclonal antibody. The combination is being evaluated primarily for its synergistic activity in inhibiting HER2 signaling, aiming to enhance anti-tumor efficacy in patients with HER2-positive colorectal cancer that is metastatic or recurrent and inoperable. This rational combination leverages both small molecule and monoclonal antibody modalities to target the HER2 pathway at multiple mechanistic levels.
- Other names
- TL938TL-938TL 938曲妥珠单抗
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TL938 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL938 + trastuzumab.